A Single Arm, Open Label, Phase II, Multicenter Study to Assess The Detection of The BRAF V600 Mutation on cfDNA From Plasma in Patients With Advanced Melanoma
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms COBIRAF
- Sponsors Roche
- 26 Aug 2019 Status changed from active, no longer recruiting to completed.
- 30 Jul 2018 Planned End Date changed from 28 Jul 2021 to 30 Jul 2019.
- 10 May 2018 Status changed from recruiting to active, no longer recruiting.